Plus Therapeutics To Present REYOBIQ And ReSPECT-LM Clinical Data On Leptomeningeal Metastases At SITC And MRF Brain Metastases Summit

Author: Benzinga Newsdesk | November 06, 2025 07:40am

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, Melanoma Research Foundation (MRF) Brain Metastases Summit 4.0 on November 9, 2025 in Alexandria, VA. Dr. Andrew Brenner, M.D., Ph.D., Professor of Medicine in the Division of Hematology and Oncology at The University of Texas Health Science Center at San Antonio will highlight the Company's REYOBIQ and ReSPECT-LM clinical trial results in the session on leptomeningeal metastases (LM) disease.

Recall, at the 2025 SNO/ASCO CNS Metastases conference in August, ReSPECT-LM Phase 1 single dose escalation trial data showed:

• REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures
• RNA sequencing and circulating tumor cell reduction consistent with tumor cell death
• No dose limiting toxicities were observed with an overall favorable safety profile up to and including the recommended phase 2 dose of 44.1 mCi
   

Posted In: PSTV